Glucagon-Like Peptide-1 Receptor Agonist Cases Reported to United States Poison Centers, 2017-2022.
Christopher E GawHannah L HaysCydney A KempSandhya KistamgariHenry A SpillerNatalie I RineAllison L RhodesMotao ZhuGary A SmithPublished in: Journal of medical toxicology : official journal of the American College of Medical Toxicology (2024)
Most GLP-1RA cases reported to US poison centers were associated with no or minimal effects and did not require referral for medical treatment; however, a notable minority of individuals experienced a serious medical outcome or healthcare facility admission. The rate of reported cases increased during the study period, including an 80.9% increase from 2021 to 2022. Opportunities exist to improve provider and patient awareness of the adverse effects of these medications.